{"url_path":"/sec/regn/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/872589/0001104659-26-075127-index.html","accession_number":"0001104659-26-075127","cik":"0000872589","ticker":"REGN","issuer_name":"REGENERON PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/872589/0001104659-26-075127-index.html","primary_entity_key":"0000872589","primary_entity_name":"REGENERON PHARMACEUTICALS, INC."},"word_count":280,"has_tables":true,"body_markdown":"**Item 5.07.**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nAt the 2026 Annual Meeting of Shareholders of\nRegeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 12, 2026, Regeneron’s\nshareholders voted on the matters set forth below.\n\n \n\n**Proposal 1 – Election of Directors**\n\n \n\nThe following nominees for Class II directors\nwere elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon\nthe following votes:\n\n \n\nNominee \nFor  \nAgainst  \nAbstain  \nBroker Non-Votes \n\nJoseph L. Goldstein, M.D. \n 72,398,297  \n 30,904,254  \n 170,603  \n 5,543,411 \n\nChristine A. Poon \n 79,409,070  \n 24,004,880  \n 59,204  \n 5,543,411 \n\nDavid P. Schenkein, M.D. \n 99,241,219  \n 4,180,107  \n 51,828  \n 5,543,411 \n\nCraig B. Thompson, M.D. \n 81,933,651  \n 21,378,567  \n 160,936  \n 5,543,411 \n\nHuda Y. Zoghbi, M.D. \n 100,665,234  \n 2,698,397  \n 109,523  \n 5,543,411 \n\n  \n    \n    \n    \n   \n\n \n\n**Proposal 2 – Ratification of Appointment of Independent Registered\nPublic Accounting Firm**\n\n \n\nThe proposal to ratify the appointment of PricewaterhouseCoopers\nLLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved\nbased upon the following votes:\n\n \n\nFor: \n 102,503,788 \n\nAgainst: \n 6,443,958 \n\nAbstain: \n 68,819 \n\n \n\n**Proposal 3 – Advisory Vote on Executive Compensation**\n\n** **\n\nThe resolution to approve, on an advisory basis,\nthe compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule\n14A filed April 24, 2026 was approved based upon the following votes:\n\n \n\nFor: \n 96,469,374 \n\nAgainst: \n 6,898,268 \n\nAbstain: \n 105,512 \n\nBroker Non-Votes: \n 5,543,411 \n\n** **\n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n**REGENERON PHARMACEUTICALS, INC.**\n\n \n \n\n \n/s/ Joseph J. LaRosa\n\n \nJoseph J. LaRosa\n\n \nExecutive Vice President, General Counsel and Secretary\n\n \n\nDate: June 17, 2026"}